Delivery Order SPE2DR25D3006-SPE2DR26FR0CF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) with a ceiling value of $1,554.35. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by November 19, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) with a ceiling value of $24,321. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by December 12, 2025, and will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) at a ceiling value of $13,135.35. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract has an ultimate completion date of December 2, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets in a 90-count quantity, with a ceiling value of $1,867.39. This firm fixed-price delivery order has an ultimate completion date of October 28, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award utilized no set-aside designation, indicating it was competitively awarded among...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Losartan-HCT 50-12.5 mg tablets in quantities of 90 units, with a contract ceiling value of $2,328.80. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The ultimate completion date is November 19, 2025, and performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count) with a ceiling value of $3,567.44. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through competitive procurement. The order is scheduled for completion by September 29, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 3, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets in a 90-count package, with a ceiling value of $1,503.73. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract calls for performance completion by December 4, 2025, with fulfillment to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 28, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) with a ceiling value of $23,163.24. This firm fixed-price delivery order, issued without a set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of December 1, 2025. The award represents a competitively awarded transaction under...
- The Defense Logistics Agency awarded a $3,671.46 delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count bottles). This firm fixed-price delivery order, with completion scheduled for December 3, 2025, represents a small-value pharmaceutical procurement supporting federal medical supply needs. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a $1,033.08 delivery order to AmerisourceBergen Drug Corp on December 5, 2025, for the supply of Losartan-HCTZ 100-12.5 mg tablets (90-count). This competitively awarded, firm fixed-price contract is scheduled for completion by December 8, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order is issued under...
- SPE2DR25D3006Indefinite Delivery Contract
- SPE2DR25D3006-SPE2DR26FR0CFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Losartan-HCTZ 50-12.5 mg tablets (90-count) with a ceiling value of $3,300.21. This is a firm fixed-price delivery order with an ultimate completion date of December 12, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal procurement requirements through open competition. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including customers such as the Defense Health Agency and U.S. Coast Guard. The company's extensive federal contract portfolio demonstrates its role as a strategic supplier within the DLA's Medical Supply Chain for generic and brand-name medications across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 12/10/25 |